Genomic Health

Genomic Health, Inc.
Public
Traded as NASDAQ: GHDX
ISIN US37244C1018
Industry Genomics
Founded August 2000 (2000-08) in Redwood City, California, United States
Founder Randy Scott
Headquarters Redwood City, California, US
Key people
  • Kimberly Popovits (CEO)
  • G. Bradley Cole (COO)
  • Steven Shak (CSO)
Products Oncotype DX
Revenue
  • Increase US$245,100,000 (2016)
  • US$212,300,000 (2015)
Number of employees
 700 (2016)
Website www.genomichealth.com
Footnotes / references
[1][2][3][4]

Genomic Health is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California.[2]

History

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte.[5] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.[6]

By 2004 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.[7] This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[8]

In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers.[9] On September 29, 2005 it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.[10]

In 2010 the Oncotype DX Colon Cancer Assay was developed. This was able to expand on their previous technology that focused on breast cancer to also work with colorectal cancer.[11] Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests.[12]

The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.[13]

In 2013 their offerings were increased with the launch of Oncotype DX Prostate Cancer Test. The test predicts some forms of prostate cancer, helping physicians determine which patients can fall under active surveillance and which cannot.[14] Knowing which tumors are threatening allow patients to avoid unneeded surgery or radiation treatments the can cause impotence and incontinence.[15]

See also

References

  1. ↑ "Leadership". Genomic Health. Retrieved 10 January 2017.
  2. 1 2 "GENOMIC HEALTH, INC.". OpenCorporates. 13 December 2016. Retrieved 10 January 2017.
  3. ↑ Chaykowsk, Kathleen (10 April 2012). "CEO’s dedication is behind Genomic Health’s cancer tests". Peninsula Press. Retrieved 10 January 2017.
  4. ↑ "Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results". Genomic Health. 1 November 2016. Retrieved 10 January 2017.
  5. ↑ Susan McKinnon; Sydel Silverman (1 June 2005). Complexities: Beyond Nature and Nurture. University of Chicago Press. p. 239. ISBN 978-0-226-50024-9. Retrieved 10 January 2017.
  6. ↑ Cook, Kevin (7 October 2013). "Genomic Health Has Sickly Stock Chart". Forbes. Retrieved 10 January 2017.
  7. ↑ WO 2004065583A3, Melody A Cobleigh, Steve Shak, Joffre B Baker, Maureen T Cronin & Steve Shak, "Gene expression markers for breast cancer prognosis", published 2005-3-3, assigned to Genomic Health and Univ Rush Medical Center
  8. ↑ Chess, Robert; Denend, Lyn; Zenios, Stefanos (2006). "Genomic Health: Launching a Paradigm Shift ... and an Innovative New Test". Stanford Graduate School of Business. Retrieved 10 January 2017.
  9. ↑ Simmers, Tim (19 July 2005). "Genomic Health files for an IPO". East Bay Times. Retrieved 10 January 2017.
  10. ↑ "GENOMIC HEALTH INC (GHDX) IPO". NASDAQ. Retrieved 10 January 2017.
  11. ↑ Webber, Elizabeth M.; Lin, Jennifer S.; Whitlock, Evelyn P. (2 September 2010). "Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.". PLoS currents. 2. PMC 2940137 Freely accessible. PMID 20877447. doi:10.1371/currents.RRN1177.
  12. ↑ Lash, Alex (20 October 2015). "What’s Your DNA Worth? The Scramble To Cash In On the Genome". exome. Retrieved 10 January 2017.
  13. ↑ "Company Timeline & Milestones". Genomic Health. Retrieved 10 January 2017.
  14. ↑ Eastman, Peggy (10 June 2013). "Oncotype DX Test for Prostate Cancer Validated, and Now Available : Oncology Times". LWW. 35 (11): 20. doi:10.1097/01.COT.0000431598.53112.cc. Retrieved 10 January 2017.
  15. ↑ Pollack, Andrew (8 May 2013). "New Test Improves Assessment of Prostate Cancer Risk, Study Says". The New York Times. Retrieved 11 January 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.